{"url_path":"/sec/hum/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/49071/0000049071-26-000027-index.html","accession_number":"0000049071-26-000027","cik":"0000049071","ticker":"HUM","issuer_name":"HUMANA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/49071/0000049071-26-000027-index.html","primary_entity_key":"0000049071","primary_entity_name":"HUMANA INC"},"word_count":495,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nMembers of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between June 1, 2026 and June 30, 2026. During these meetings, the Company intends to reaffirm its guidance of at least $8.36 in diluted earnings per common share (“EPS”) or at least $9.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2026 (“FY 2026”). This guidance is consistent with the guidance issued in Humana’s press release dated April 29, 2026.\n\nThe Company has included Adjusted (non-GAAP) EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company’s core operating performance over time. Consequently, management uses Adjusted (non-GAAP) EPS as a consistent indicator of the Company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted (non-GAAP) EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. Adjusted (non-GAAP) EPS is subject to inherent limitations and may differ from the similarly titled measure used by other companies. A reconciliation of GAAP EPS to Adjusted (non-GAAP) EPS follows:\n\nDiluted earnings per shareFY 2026 Guidance\n\nGAAPat least $8.36\n\nAmortization of identifiable intangibles0.30 \n\nPut/call valuation adjustments associated with the company's non-consolidating\nminority interest investments (a)\n(0.28)\n\nValue creation initiatives (a)0.81 \n\nCumulative net tax impact(0.19)\n\nAdjusted (non-GAAP) – FY 2026 projected (a)at least $9.00\n\n(a)FY 2026 GAAP EPS guidance and FY 2026 Adjusted (non-GAAP) EPS guidance exclude the impact of value changes to items that have not yet been recognized or cannot currently be reasonably estimated at this time. The Company does not expect changes to its FY 2026 Adjusted (non-GAAP) EPS guidance. The Company does expect potential changes to its FY 2026 GAAP EPS guidance due to its ongoing value creation and other strategic initiatives.\n\nCautionary Statement\n\nThis Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, generally including the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions that are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the Company’s SEC filings.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nHUMANA INC.\n\nBY:/s/ John-Paul W. Felter\n\nJohn-Paul W. Felter\n\nSenior Vice President, Chief Accounting Officer & Controller\n\n(Principal Accounting Officer)\n\nDated: June 1, 2026"}